Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Epidemiology of Sjögren syndrome

Nature Reviews Rheumatology volume 20, pages 158–169 (2024)Cite this article

Subjects

Abstract

Sjögren syndrome is a phenotypically varied autoimmune disorder that can occur alone in primary Sjögren syndrome or in association with other connective tissue diseases (CTDs), including rheumatoid arthritis, systemic lupus erythematosus (SLE) and systemic sclerosis (SSc). The estimation of the prevalence and incidence of Sjögren syndrome varies depending on diagnostic criteria and study design, making it difficult to estimate geographical and temporal trends. Nonetheless, disease phenotype is influenced by geographical origin, which is a risk factor for systemic activity. Whether mortality in primary Sjögren syndrome is increased compared with that of the general population is not yet known, but extra-glandular manifestations, in particular lymphomas, are clear risk factors for mortality. In CTDs associated with Sjögren syndrome, lymphoma risk seems higher than that of patients with CTD alone, and there is potentially lower disease activity in SLE with Sjögren syndrome and in SSc with Sjögren syndrome than in SLE or SSc alone.

Key points

  • Primary Sjögren syndrome (pSS) affects mostly women, with age at disease onset as well as systemic activity varying according to geographical origin.

  • Assessment of the prevalence of pSS varies according to study methodology, but can be estimated at between 0.01% and 0.05%, although some countries might be under-represented in this estimation.

  • Mortality in pSS seems to be elevated predominantly in patients with extra-glandular manifestations, pulmonary involvement and non-Hodgkin lymphoma.

  • pSS is the autoimmune disease with the most important increased risk of non-Hodgkin lymphoma, especially among patients with extra-glandular manifestations or systemic activity, low complement levels, cryoglobulinaemic vasculitis or rheumatoid factor positivity.

  • Sjögren syndrome can be associated with other connective tissue diseases, mainly rheumatoid arthritis, systemic lupus erythematosus and systemic sclerosis.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Mapped prevalence of primary Sjögren syndrome.

Similar content being viewed by others

References

  1. Mariette, X. & Criswell, L. A. Primary Sjögren’s syndrome. N. Engl. J. Med. 378, 931–939 (2018).

    Article  PubMed  Google Scholar 

  2. Champey, J. et al. Quality of life and psychological status in patients with primary Sjögren’s syndrome and sicca symptoms without autoimmune features. Arthritis Rheum. 55, 451–457 (2006).

    Article  PubMed  Google Scholar 

  3. Cui, Y. et al. Anxiety and depression in primary Sjögren’s syndrome: a cross-sectional study. BMC Psychiatry 18, 131 (2018).

    Article  PubMed  PubMed Central  Google Scholar 

  4. Milin, M. et al. Sicca symptoms are associated with similar fatigue, anxiety, depression, and quality-of-life impairments in patients with and without primary Sjögren’s syndrome. Jt. Bone Spine 83, 681–685 (2016).

    Article  Google Scholar 

  5. Font, J. et al. Pure sensory neuropathy in primary Sjögren’s syndrome. Longterm prospective followup and review of the literature. J. Rheumatol. 30, 1552–1557 (2003).

    PubMed  Google Scholar 

  6. Huang, H., Xie, W., Geng, Y., Fan, Y. & Zhang, Z. Mortality in patients with primary Sjögren’s syndrome: a systematic review and meta-analysis. Rheumatology 60, 4029–4038 (2021).

    Article  PubMed  Google Scholar 

  7. Brito-Zerón, P. et al. How immunological profile drives clinical phenotype. Clin. Exp. Rheumatol. 112, 102–112 (2018).

    Google Scholar 

  8. Gottenberg, J.-E. et al. Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjögren’s syndrome. Data at enrollment in the prospective ASSESS cohort. PLoS ONE 8, e59868 (2013).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  9. Quartuccio, L. et al. BLyS upregulation in Sjögren’s syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology 52, 276–281 (2013).

    Article  CAS  PubMed  Google Scholar 

  10. Kollert, F. & Fisher, B. A. Equal rights in autoimmunity: is Sjögren’s syndrome ever ‘secondary’? Rheumatology 59, 1218–1225 (2020).

    Article  CAS  PubMed  Google Scholar 

  11. Mavragani, C. P. & Moutsopoulos, H. M. Primary versus secondary Sjögren syndrome: is it time to reconsider these terms? J. Rheumatol. 46, 665–666 (2019).

    Article  CAS  PubMed  Google Scholar 

  12. Shiboski, S. et al. American College of Rheumatology classification criteria for Sjögren’s syndrome: a data-driven, expert consensus approach in the SICCA cohort. Arthritis Care Res. 64, 475–487 (2012).

    Article  CAS  Google Scholar 

  13. Baldini, C., Bartoloni, E. & Bombardieri, M. Highlights of the 15th international symposium on Sjögren’s syndrome. Clin. Exp. Rheumatol. 40, 2201–2210 (2022).

    PubMed  Google Scholar 

  14. Rasmussen, A. et al. Previous diagnosis of Sjögren’s syndrome as rheumatoid arthritis or systemic lupus erythematosus. Rheumatology 55, 1195–1201 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  15. Calvo, F., Karras, B. T., Phillips, R., Kimball, A. M. & Wolf, F. Diagnoses, syndromes, and diseases: a knowledge representation problem. AMIA Annu. Symp. Proc. 2003, 802 (2003).

    PubMed  PubMed Central  Google Scholar 

  16. Baer, A. N. & Hammitt, K. M. Sjögren’s disease, not syndrome. Arthritis Rheumatol. 73, 1347–1348 (2021).

    Article  PubMed  Google Scholar 

  17. Coll, J. et al. Prevalence of Sjögren’s syndrome in autoimmune diseases. Ann. Rheum. Dis. 46, 286–289 (1987).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Moutsopoulos, H. M., Mann, D. L., Johnson, A. H. & Chused, T. M. Genetic differences between primary and secondary sicca syndrome. N. Engl. J. Med. 301, 761–763 (1979).

    Article  CAS  PubMed  Google Scholar 

  19. Moutsopoulos, H. M. et al. Sjögren’s syndrome (Sicca syndrome): current issues. Ann. Intern. Med. 92, 212–226 (1980).

    Article  CAS  PubMed  Google Scholar 

  20. Kassan, S. S. et al. Increased risk of lymphoma in sicca syndrome. Ann. Intern. Med. 89, 888–892 (1978).

    Article  CAS  PubMed  Google Scholar 

  21. Hassold, N., Seror, R., Mariette, X. & Nocturne, G. Characteristics of Sjögren’s syndrome associated with rheumatoid arthritis. RMD Open 8, e002234 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

  22. Kauppi, M., Pukkala, E. & Isomäki, H. Elevated incidence of hematologic malignancies in patients with Sjögren’s syndrome compared with patients with rheumatoid arthritis (Finland). Cancer Causes Control 8, 201–204 (1997).

    Article  CAS  PubMed  Google Scholar 

  23. He, J. et al. Characteristics of Sjogren’s syndrome in rheumatoid arthritis. Rheumatology 52, 1084–1089 (2013).

    Article  CAS  PubMed  Google Scholar 

  24. Johansson, A.-K. et al. Self-reported dry mouth in Swedish population samples aged 50, 65 and 75 years. Gerodontology 29, e107–e115 (2012).

    Article  PubMed  Google Scholar 

  25. Schaumberg, D. A., Sullivan, D. A., Buring, J. E. & Dana, M. R. Prevalence of dry eye syndrome among US women. Am. J. Ophthalmol. 136, 318–326 (2003).

    Article  PubMed  Google Scholar 

  26. Stapleton, F. et al. TFOS DEWS II epidemiology report. Ocul. Surf. 15, 334–365 (2017).

    Article  PubMed  Google Scholar 

  27. Vitali, C. et al. Assessment of the European classification criteria for Sjögren’s syndrome in a series of clinically defined cases: results of a prospective multicentre study. The European Study Group on Diagnostic Criteria for Sjögren’s Syndrome. Ann. Rheum. Dis. 55, 116–121 (1996).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Vitali, C. et al. Preliminary criteria for the classification of Sjögren’s syndrome. Results of a prospective concerted action supported by the European Community. Arthritis Rheum. 36, 340–347 (1993).

    Article  CAS  PubMed  Google Scholar 

  29. Vitali, C. et al. Classification criteria for Sjögren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann. Rheum. Dis. 61, 554–558 (2002).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Tsuboi, H. et al. Comparison of performance of the 2016 ACR-EULAR classification criteria for primary Sjögren’s syndrome with other sets of criteria in Japanese patients. Ann. Rheum. Dis. 76, 1980–1985 (2017).

    Article  CAS  PubMed  Google Scholar 

  31. Le Goff, M. et al. Comparison of 2002 AECG and 2016 ACR/EULAR classification criteria and added value of salivary gland ultrasonography in a patient cohort with suspected primary Sjögren’s syndrome. Arthritis Res. Ther. 19, 269 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  32. Brito-Zerón, P. et al. Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren’s syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data Sjögren Project Consortium. Ann. Rheum. Dis. 76, 1042–1050 (2017).

    Article  PubMed  Google Scholar 

  33. Retamozo, S. et al. Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium. Clin. Exp. Rheumatol. 39, 166–174 (2021).

    Article  PubMed  Google Scholar 

  34. Brito-Zerón, P. et al. Epidemiological profile and north-south gradient driving baseline systemic involvement of primary Sjögren’s syndrome. Rheumatology 59, 2350–2359 (2020).

    Article  PubMed  Google Scholar 

  35. Flament, T. et al. Pulmonary manifestations of Sjögren’s syndrome. Eur. Respir. Rev. 25, 110–123 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

  36. Ramírez Sepúlveda, J. I., Kvarnström, M., Brauner, S., Baldini, C. & Wahren-Herlenius, M. Difference in clinical presentation between women and men in incident primary Sjögren’s syndrome. Biol. Sex. Differ. 8, 16 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  37. Wei, L. et al. Patients with early-onset primary Sjögren’s syndrome have distinctive clinical manifestations and circulating lymphocyte profiles. Rheumatology 61, 597–605 (2022).

    Article  CAS  PubMed  Google Scholar 

  38. Goules, A. V. et al. Primary Sjögren’s syndrome of early and late onset: distinct clinical phenotypes and lymphoma development. Front. Immunol. 11, 594096 (2020).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Beydon, M. et al. Impact of patient ancestry on heterogeneity of Sjögren’s disease. RMD Open 9, e002955 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

  40. Dafni, D., Ag, T., P, S., Fn, S. & Hm, M. Prevalence of Sjögren’s syndrome in a closed rural community. Ann. Rheum. Dis. 56, 521–525 (1997).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Tomsic, M., Logar, D., Grmek, M., Perkovic, T. & Kveder, T. Prevalence of Sjögren’s syndrome in Slovenia. Rheumatology 38, 164–170 (1999).

    Article  CAS  PubMed  Google Scholar 

  42. Trontzas, P. I. & Andrianakos, A. A. Sjogren’s syndrome: a population based study of prevalence in Greece. The ESORDIG study. Ann. Rheum. Dis. 64, 1240–1241 (2005).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Alamanos, Y. et al. Epidemiology of primary Sjögren’s syndrome in north-west Greece, 1982–2003. Rheumatology 45, 187–191 (2006).

    Article  ADS  CAS  PubMed  Google Scholar 

  44. Maldini, C. et al. Epidemiology of primary Sjögren’s syndrome in a French multiracial/multiethnic area. Arthritis Care Res. 66, 454–463 (2014).

    Article  Google Scholar 

  45. Xiang, Y.-J. & Dai, S.-M. Prevalence of rheumatic diseases and disability in China. Rheumatol. Int. 29, 481–490 (2009).

    Article  PubMed  Google Scholar 

  46. See, L.-C., Kuo, C.-F., Chou, I.-J., Chiou, M.-J. & Yu, K.-H. Sex- and age-specific incidence of autoimmune rheumatic diseases in the Chinese population: a Taiwan population-based study. Semin. Arthritis Rheum. 43, 381–386 (2013).

    Article  PubMed  Google Scholar 

  47. Seror, R. et al. Pos0024 estimated prevalence, incidence and healthcare costs of Sjögren’s syndrome in France: a national claims-based study. Ann. Rheum. Dis. 80, 214–215 (2021).

    Article  Google Scholar 

  48. Maciel, G., Crowson, C. S., Matteson, E. L. & Cornec, D. Prevalence of primary Sjögren’s syndrome in a US population-based cohort. Arthritis Care Res. 69, 1612–1616 (2017).

    Article  Google Scholar 

  49. Nocturne, G. et al. Primary Sjögren’s syndrome prevalence: What if Sjögren was right after all? Comment on the article by Maciel et al. Arthritis Care Res. 70, 951–953 (2018).

    Article  Google Scholar 

  50. Valim, V. et al. Primary Sjögren’s syndrome prevalence in a major metropolitan area in Brazil. Rev. Bras. Reumatol. 53, 24–34 (2013).

    PubMed  Google Scholar 

  51. Qin, B. et al. Epidemiology of primary Sjögren’s syndrome: a systematic review and meta-analysis. Ann. Rheum. Dis. 74, 1983–1989 (2015).

    Article  CAS  PubMed  Google Scholar 

  52. Pillemer, S. R. et al. Incidence of physician-diagnosed primary Sjögren syndrome in residents of Olmsted County, Minnesota. Mayo Clin. Proc. 76, 593–599 (2001).

    Article  CAS  PubMed  Google Scholar 

  53. Izmirly, P. M. et al. The incidence and prevalence of adult primary Sjögren’s syndrome in New York County. Arthritis Care Res. 71, 949–960 (2019).

    Article  Google Scholar 

  54. Weng, M.-Y., Huang, Y.-T., Liu, M.-F. & Lu, T.-H. Incidence and mortality of treated primary Sjogren’s syndrome in Taiwan: a population-based study. J. Rheumatol. 38, 706–708 (2011).

    Article  PubMed  Google Scholar 

  55. Yu, K.-H., See, L.-C., Kuo, C.-F., Chou, I.-J. & Chou, M.-J. Prevalence and incidence in patients with autoimmune rheumatic diseases: a nationwide population-based study in Taiwan. Arthritis Care Res. 65, 244–250 (2013).

    Article  Google Scholar 

  56. Jin, L., Dai, M., Li, C., Wang, J. & Wu, B. Risk factors for primary Sjögren’s syndrome: a systematic review and meta-analysis. Clin. Rheumatol. 42, 327–338 (2023).

    Article  PubMed  Google Scholar 

  57. Karlson, E. W. et al. Gene-environment interaction between HLA-DRB1 shared epitope and heavy cigarette smoking in predicting incident rheumatoid arthritis. Ann. Rheum. Dis. 69, 54–60 (2010).

    Article  CAS  PubMed  Google Scholar 

  58. Mofors, J. et al. Cigarette smoking patterns preceding primary Sjögren’s syndrome. RMD Open 6, e001402 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  59. Ben-Eli, H. et al. Shared medical and environmental risk factors in dry eye syndrome, Sjogren’s syndrome, and B-cell non-Hodgkin lymphoma: a case-control study. J. Immunol. Res. 2019, 9060842 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  60. Olsson, P., Turesson, C., Mandl, T., Jacobsson, L. & Theander, E. Cigarette smoking and the risk of primary Sjögren’s syndrome: a nested case control study. Arthritis Res. Ther. 19, 50 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  61. Priori, R. et al. Risk factors for Sjögren’s syndrome: a case-control study. Clin. Exp. Rheumatol. 25, 378–384 (2007).

    CAS  PubMed  Google Scholar 

  62. Salliot, C. et al. Female hormonal exposures and risk of rheumatoid arthritis in the French E3N-EPIC cohort study. Rheumatology 60, 4790–4800 (2021).

    Article  CAS  PubMed  Google Scholar 

  63. McCoy, S. S., Sampene, E. & Baer, A. N. Association of Sjögren’s syndrome with reduced lifetime sex hormone exposure: a case-control study. Arthritis Care Res. 72, 1315–1322 (2020).

    Article  CAS  Google Scholar 

  64. Karaiskos, D. et al. Psychopathological and personality features in primary Sjogren’s syndrome — associations with autoantibodies to neuropeptides. Rheumatology 49, 1762–1769 (2010).

    Article  CAS  PubMed  Google Scholar 

  65. Meng, F., Ren, S., Meng, Y., Tao, N. & Zhang, J. Association between stressful life events and female primary Sjogren’s syndrome and their role in disease activity: a retrospective case-control study in China. Neuropsychiatr. Dis. Treat. 17, 213–220 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  66. Machowicz, A. et al. Mediterranean diet and risk of Sjögren’s syndrome. Clin. Exp. Rheumatol. 38, 216–221 (2020).

    PubMed  Google Scholar 

  67. Singh, A. G., Singh, S. & Matteson, E. L. Rate, risk factors and causes of mortality in patients with Sjögren’s syndrome: a systematic review and meta-analysis of cohort studies. Rheumatology 55, 450–460 (2016).

    PubMed  Google Scholar 

  68. Thomas, E., Symmons, D. P. M., Brewster, D. H., Black, R. J. & Macfarlane, G. J. National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. J. Rheumatol. 30, 958–965 (2003).

    PubMed  Google Scholar 

  69. Brito-Zerón, P. et al. Systemic activity and mortality in primary Sjögren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients. Ann. Rheum. Dis. 75, 348–355 (2016).

    Article  PubMed  Google Scholar 

  70. Kim, H. J. et al. Incidence, mortality, and causes of death in physician-diagnosed primary Sjögren’s syndrome in Korea: a nationwide, population-based study. Semin. Arthritis Rheum. 47, 222–227 (2017).

    Article  PubMed  Google Scholar 

  71. Yazisiz, V. et al. Survival analysis of patients with Sjögren’s syndrome in Turkey: a tertiary hospital-based study. Clin. Rheumatol. 39, 233–241 (2020).

    Article  PubMed  Google Scholar 

  72. Maciel, G., Crowson, C. S., Matteson, E. L. & Cornec, D. Incidence and mortality of physician-diagnosed primary Sjögren’s syndrome: time trends over a 40-year period in a population-based cohort in the United States. Mayo Clin. Proc. 92, 734–743 (2017).

    Article  PubMed  Google Scholar 

  73. Theander, E., Manthorpe, R. & Jacobsson, L. T. H. Mortality and causes of death in primary Sjögren’s syndrome: a prospective cohort study. Arthritis Rheum. 50, 1262–1269 (2004).

    Article  PubMed  Google Scholar 

  74. Ramos-Casals, M. et al. Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren’s syndrome. Rheumatology 44, 89–94 (2005).

    Article  CAS  PubMed  Google Scholar 

  75. Ioannidis, J. P. A., Vassiliou, V. A. & Moutsopoulos, H. M. Long-term risk of mortality and lymphoproliferative disease and predictive classification of primary Sjögren’s syndrome. Arthritis Rheum. 46, 741–747 (2002).

    Article  PubMed  Google Scholar 

  76. Skopouli, F. N., Dafni, U., Ioannidis, J. P. & Moutsopoulos, H. M. Clinical evolution, and morbidity and mortality of primary Sjögren’s syndrome. Semin. Arthritis Rheum. 29, 296–304 (2000).

    Article  CAS  PubMed  Google Scholar 

  77. Horvath, I. F., Szanto, A., Papp, G. & Zeher, M. Clinical course, prognosis, and cause of death in primary Sjögren’s syndrome. J. Immunol. Res. 2014, 647507 (2014).

    Article  PubMed  PubMed Central  Google Scholar 

  78. Palm, O. et al. Clinical pulmonary involvement in primary Sjogren’s syndrome: prevalence, quality of life and mortality — a retrospective study based on registry data. Rheumatology 52, 173–179 (2013).

    Article  PubMed  Google Scholar 

  79. Brito-Zerón, P. et al. Characterization and risk estimate of cancer in patients with primary Sjögren syndrome. J. Hematol. Oncol. 10, 90 (2017).

    Article  PubMed  PubMed Central  Google Scholar 

  80. Voulgarelis, M. et al. Prognosis and outcome of non-Hodgkin lymphoma in primary Sjögren syndrome. Medicine 91, 1–9 (2012).

    Article  PubMed  Google Scholar 

  81. Theander, E. et al. Lymphoma and other malignancies in primary Sjögren’s syndrome: a cohort study on cancer incidence and lymphoma predictors. Ann. Rheum. Dis. 65, 796–803 (2006).

    Article  CAS  PubMed  Google Scholar 

  82. Johnsen, S. J. et al. Risk of non-Hodgkin’s lymphoma in primary Sjögren’s syndrome: a population-based study. Arthritis Care Res. 65, 816–821 (2013).

    Article  ADS  Google Scholar 

  83. Fallah, M. et al. Autoimmune diseases associated with non-Hodgkin lymphoma: a nationwide cohort study. Ann. Oncol. 25, 2025–2030 (2014).

    Article  CAS  PubMed  Google Scholar 

  84. Nocturne, G. et al. Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sjögren’s syndrome: characteristics and predictors of lymphoma in primary Sjögren’s syndrome. Arthritis Rheumatol. 68, 977–985 (2016).

    Article  CAS  PubMed  Google Scholar 

  85. Wang, L.-H., Wang, W.-M., Lin, C.-Y., Lin, S.-H. & Shieh, C.-C. Bidirectional relationship between primary Sjögren syndrome and non-Hodgkin lymphoma: a nationwide Taiwanese population-based study. J. Rheumatol. 47, 1374–1378 (2020).

    Article  PubMed  Google Scholar 

  86. Nocturne, G., Pontarini, E., Bombardieri, M. & Mariette, X. Lymphomas complicating primary Sjögren’s syndrome: from autoimmunity to lymphoma. Rheumatology 60, 3513–3521 (2021).

    Article  CAS  PubMed  Google Scholar 

  87. Stott, D. I., Hiepe, F., Hummel, M., Steinhauser, G. & Berek, C. Antigen-driven clonal proliferation of B cells within the target tissue of an autoimmune disease. The salivary glands of patients with Sjögren’s syndrome. J. Clin. Invest. 102, 938–946 (1998).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Bende, R. J. et al. Among B cell non-Hodgkin’s lymphomas, MALT lymphomas express a unique antibody repertoire with frequent rheumatoid factor reactivity. J. Exp. Med. 201, 1229–1241 (2005).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Zhang, W. et al. Incidence of malignancy in primary Sjogren’s syndrome in a Chinese cohort. Rheumatology 49, 571–577 (2010).

    Article  PubMed  Google Scholar 

  90. Solans-Laqué, R. et al. Risk, predictors, and clinical characteristics of lymphoma development in primary Sjögren’s syndrome. Semin. Arthritis Rheum. 41, 415–423 (2011).

    Article  PubMed  Google Scholar 

  91. Chatzis, L. et al. A biomarker for lymphoma development in Sjogren’s syndrome: salivary gland focus score. J. Autoimmun. 121, 102648 (2021).

    Article  CAS  PubMed  Google Scholar 

  92. Risselada, A. P. et al. The prognostic value of routinely performed minor salivary gland assessments in primary Sjögren’s syndrome. Ann. Rheum. Dis. 73, 1537–1540 (2014).

    Article  PubMed  Google Scholar 

  93. Quartuccio, L. et al. Biomarkers of lymphoma in Sjögren’s syndrome and evaluation of the lymphoma risk in prelymphomatous conditions: results of a multicenter study. J. Autoimmun. 51, 75–80 (2014).

    Article  PubMed  Google Scholar 

  94. Fujita, M. et al. Correlation between dry eye and rheumatoid arthritis activity. Am. J. Ophthalmol. 140, 808–813 (2005).

    Article  PubMed  Google Scholar 

  95. Antero, D. C., Parra, A. G. M., Miyazaki, F. H., Gehlen, M. & Skare, T. L. Secondary Sjögren’s syndrome and disease activity of rheumatoid arthritis. Rev. Assoc. Med. Bras. 57, 319–322 (2011).

    Article  PubMed  Google Scholar 

  96. Harrold, L. R. et al. Prevalence of Sjögren’s syndrome associated with rheumatoid arthritis in the USA: an observational study from the Corrona registry. Clin. Rheumatol. 39, 1899–1905 (2020).

    Article  PubMed  PubMed Central  Google Scholar 

  97. Brown, L. E. et al. Clinical characteristics of RA patients with secondary SS and association with joint damage. Rheumatology 54, 816–820 (2015).

    Article  CAS  PubMed  Google Scholar 

  98. Haga, H.-J., Naderi, Y., Moreno, A. M. & Peen, E. A study of the prevalence of sicca symptoms and secondary Sjögren’s syndrome in patients with rheumatoid arthritis, and its association to disease activity and treatment profile. Int. J. Rheum. Dis. 15, 284–288 (2012).

    Article  PubMed  Google Scholar 

  99. Gottenberg, J.-E. et al. Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjögren’s syndrome. Ann. Rheum. Dis. 64, 114–117 (2005).

    Article  CAS  PubMed  Google Scholar 

  100. Atzeni, F. et al. Anti-cyclic citrullinated peptide antibodies in primary Sjögren syndrome may be associated with non-erosive synovitis. Arthritis Res. Ther. 10, R51 (2008).

    Article  PubMed  PubMed Central  Google Scholar 

  101. McDonagh, J. E. & Isenberg, D. A. Development of additional autoimmune diseases in a population of patients with systemic lupus erythematosus. Ann. Rheum. Dis. 59, 230–232 (2000).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Manoussakis, M. N. et al. Sjögren’s syndrome associated with systemic lupus erythematosus: clinical and laboratory profiles and comparison with primary Sjögren’s syndrome. Arthritis Rheum. 50, 882–891 (2004).

    Article  PubMed  Google Scholar 

  103. Pan, H. F. et al. Clinical and laboratory profiles of systemic lupus erythematosus associated with Sjögren syndrome in China: a study of 542 patients. Clin. Rheumatol. 27, 339–343 (2008).

    Article  PubMed  Google Scholar 

  104. Baer, A. N., Maynard, J. W., Shaikh, F., Magder, L. S. & Petri, M. Secondary Sjogren’s syndrome in systemic lupus erythematosus defines a distinct disease subset. J. Rheumatol. 37, 1143–1149 (2010).

    Article  PubMed  Google Scholar 

  105. Aggarwal, R., Anaya, J.-M., Koelsch, K. A., Kurien, B. T. & Scofield, R. H. Association between secondary and primary Sjögren’s syndrome in a large collection of lupus families. Autoimmune Dis. 2015, 298506 (2015).

    PubMed  PubMed Central  Google Scholar 

  106. Szanto, A. et al. Clinical, serologic, and genetic profiles of patients with associated Sjögren’s syndrome and systemic lupus erythematosus. Hum. Immunol. 67, 924–930 (2006).

    Article  CAS  PubMed  Google Scholar 

  107. Nossent, J. C. & Swaak, A. J. Systemic lupus erythematosus VII: frequency and impact of secondary Sjøgren’s syndrome. Lupus 7, 231–234 (1998).

    Article  CAS  PubMed  Google Scholar 

  108. Xu, D. et al. Sjögren’s syndrome-onset lupus patients have distinctive clinical manifestations and benign prognosis: a case–control study. Lupus 19, 197–200 (2010).

    Article  CAS  PubMed  Google Scholar 

  109. Yao, Q., Altman, R. D. & Wang, X. Systemic lupus erythematosus with Sjögren syndrome compared to systemic lupus erythematosus alone: a meta-analysis. J. Clin. Rheumatol. 18, 28–32 (2012).

    Article  PubMed  Google Scholar 

  110. Ramos-Casals, M. et al. Atypical autoantibodies in patients with primary Sjögren syndrome: clinical characteristics and follow-up of 82 cases. Semin. Arthritis Rheumatism 35, 312–321 (2006).

    Article  CAS  PubMed  Google Scholar 

  111. Assan, F., Seror, R., Mariette, X. & Nocturne, G. New 2019 SLE EULAR/ACR classification criteria are valuable for distinguishing patients with SLE from patients with pSS. Ann. Rheum. Dis. 80, e122–e122 (2021).

    Article  PubMed  Google Scholar 

  112. Hadj Said, M., Foletti, J. M., Graillon, N., Guyot, L. & Chossegros, C. Orofacial manifestations of scleroderma. A literature review. Rev. Stomatol. Chir. Maxillofac. Chir. Orale 117, 322–326 (2016).

    CAS  PubMed  Google Scholar 

  113. Avouac, J. et al. Systemic sclerosis-associated Sjögren’s syndrome and relationship to the limited cutaneous subtype: results of a prospective study of sicca syndrome in 133 consecutive patients. Arthritis Rheum. 54, 2243–2249 (2006).

    Article  CAS  PubMed  Google Scholar 

  114. Kobak, S., Oksel, F., Aksu, K. & Kabasakal, Y. The frequency of sicca symptoms and Sjögren’s syndrome in patients with systemic sclerosis. Int. J. Rheum. Dis. 16, 88–92 (2013).

    Article  PubMed  Google Scholar 

  115. Avouac, J. et al. Associated autoimmune diseases in systemic sclerosis define a subset of patients with milder disease: results from 2 large cohorts of European Caucasian patients. J. Rheumatol. 37, 608–614 (2010).

    Article  PubMed  Google Scholar 

  116. Baldini, C. et al. Overlap of ACA-positive systemic sclerosis and Sjögren’s syndrome: a distinct clinical entity with mild organ involvement but at high risk of lymphoma. Clin. Exp. Rheumatol. 31, 272–280 (2013).

    PubMed  Google Scholar 

  117. Bautista-Vargas, M., Vivas, A. J. & Tobón, G. J. Minor salivary gland biopsy: its role in the classification and prognosis of Sjögren’s syndrome. Autoimmun. Rev. 19, 102690 (2020).

    Article  PubMed  Google Scholar 

  118. Baer, A. N., Medrano, L., McAdams-DeMarco, M. & Gniadek, T. J. Anti-centromere antibodies are associated with more severe exocrine glandular dysfunction in Sjögren’s syndrome: analysis of the Sjögren’s International Collaborative Clinical Alliance cohort. Arthritis Care Res. 68, 1554–1559 (2016).

    Article  CAS  Google Scholar 

  119. Mercer, L. K. et al. Risk of cancer in patients receiving non-biologic disease-modifying therapy for rheumatoid arthritis compared with the UK general population. Rheumatology 52, 91–98 (2013).

    Article  PubMed  Google Scholar 

  120. Bernatsky, S. et al. Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann. Rheum. Dis. 73, 138–142 (2014).

    Article  CAS  PubMed  Google Scholar 

  121. Essouma, M., Noubiap, J. J., Singwe-Ngandeu, M. & Hachulla, E. Epidemiology of Sjögren syndrome in Africa: a scoping review. J. Clin. Rheumatol. 28, e240–e244 (2022).

    Article  PubMed  Google Scholar 

  122. McCoy, S. S. et al. Symptom-based cluster analysis categorizes Sjögren’s disease subtypes: an international cohort study highlighting disease severity and treatment discordance. Arthritis Rheumatol. 74, 1569–1579 (2022).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  123. Nguyen, Y. et al. Determination of distinct phenotypes of primary Sjögren’s disease using cluster analysis based on clinical and biological manifestations: data from 458 patients from the Paris Saclay Sjögren’s Syndrome Cohort [POS0165]. Ann. Rheum. Dis. 82, 305–306 (2023).

    Google Scholar 

  124. Soret, P. et al. A new molecular classification to drive precision treatment strategies in primary Sjögren’s syndrome. Nat. Commun. 12, 3523 (2021).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  125. Tarn, J. R. et al. Symptom-based stratification of patients with primary Sjögren’s syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. Lancet Rheumatol. 1, e85–e94 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

  126. Seror, R. et al. Development and preliminary validation of the Sjögren’s Tool for Assessing Response (STAR): a consensual composite score for assessing treatment effect in primary Sjögren’s syndrome. Ann. Rheum. Dis. 81, 979–989 (2022).

    Article  PubMed  Google Scholar 

  127. Goules, A. V., Exarchos, T. P., Fotiadis, D. I. & Tzioufas, A. The clinical and technical impact of the HarmonicSS project. Clin. Exp. Rheumatol. 39, 17–19 (2021).

    Article  PubMed  Google Scholar 

  128. Wakai, K. et al. Estimated prevalence of Sjogren’s syndrome in Japan: findings from a nationwide epidemiological survey. J. Epidemiol. 5, 125–129 (1995).

    Article  Google Scholar 

  129. Thomas, E., Hay, E. M., Hajeer, A. & Silman, A. J. Sjögren’s syndrome: a community-based study of prevalence and impact. Br. J. Rheumatol. 37, 1069–1076 (1998).

    Article  CAS  PubMed  Google Scholar 

  130. Bowman, S. J., Ibrahim, G. H., Holmes, G., Hamburger, J. & Ainsworth, J. R. Estimating the prevalence among Caucasian women of primary Sjögren’s syndrome in two general practices in Birmingham, UK. Scand. J. Rheumatol. 33, 39–43 (2004).

    Article  CAS  PubMed  Google Scholar 

  131. Kabasakal, Y. et al. The prevalence of Sjögren’s syndrome in adult women. Scand. J. Rheumatol. 35, 379–383 (2006).

    Article  CAS  PubMed  Google Scholar 

  132. Eaton, W. W., Rose, N. R., Kalaydjian, A., Pedersen, M. G. & Mortensen, P. B. Epidemiology of autoimmune diseases in Denmark. J. Autoimmun. 29, 1–9 (2007).

    Article  PubMed  PubMed Central  Google Scholar 

  133. Birlik, M. et al. Prevalence of primary Sjogren’s syndrome in Turkey: a population-based epidemiological study. Int. J. Clin. Pract. 63, 954–961 (2009).

    Article  CAS  PubMed  Google Scholar 

  134. Anagnostopoulos, I. et al. The prevalence of rheumatic diseases in central Greece: a population survey. BMC Musculoskelet. Disord. 11, 98 (2010).

    Article  PubMed  PubMed Central  Google Scholar 

  135. Gøransson, L. et al. The point prevalence of clinically relevant primary Sjögren’s syndrome in two Norwegian counties. Scand. J. Rheumatol. 40, 221–224 (2011).

    Article  PubMed  Google Scholar 

  136. Sardu, C. et al. Population based study of 12 autoimmune diseases in Sardinia, Italy: prevalence and comorbidity. PLoS ONE 7, e32487 (2012).

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  137. Tsuboi, H. et al. Primary and secondary surveys on epidemiology of Sjögren’s syndrome in Japan. Mod. Rheumatol. 24, 464–470 (2014).

    Article  PubMed  Google Scholar 

  138. Fujibayashi, T., Sugai, S., Miyasaka, N., Hayashi, Y. & Tsubota, K. Revised Japanese criteria for Sjögren’s syndrome (1999): availability and validity. Mod. Rheumatol. 14, 425–434 (2004).

    Article  PubMed  Google Scholar 

  139. Moriyama, I. M. The eighth revision of the International Classification of Diseases. Am. J. Public Health Nations Health 56, 1277–1280 (1966).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  140. Brämer, G. R. International statistical classification of diseases and related health problems. Tenth revision. World Health Stat. Q 41, 32–36 (1988).

  141. Manthorpe, R., Oxholm, P., Prause, J. U. & Schiødt, M. The Copenhagen criteria for Sjögren’s syndrome. Scand. J. Rheumatol. Suppl. 61, 19–21 (1986).

    CAS  PubMed  Google Scholar 

  142. Slee, V. N. The International Classification of Diseases: ninth revision (ICD-9). Ann. Intern. Med. 88, 424–426 (1978).

    Article  CAS  PubMed  Google Scholar 

  143. Pleisivicnik, M. et al. Incidence of primary Sjogren’s syndrome in Slovenia. Ann. Rheum. Dis. 63, 874–876 (2004).

    Article  Google Scholar 

  144. Valesini, G. et al. Differential risk of non-Hodgkin’s lymphoma in Italian patients with primary Sjögren’s syndrome. J. Rheumatol. 24, 2376–2380 (1997).

    CAS  PubMed  Google Scholar 

  145. Pertovaara, M., Pukkala, E., Laippala, P., Miettinen, A. & Pasternack, A. A longitudinal cohort study of Finnish patients with primary Sjögren’s syndrome: clinical, immunological, and epidemiological aspects. Ann. Rheum. Dis. 60, 467–472 (2001).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  146. Weng, M.-Y., Huang, Y.-T., Liu, M.-F. & Lu, T.-H. Incidence of cancer in a nationwide population cohort of 7852 patients with primary Sjogren’s syndrome in Taiwan. Ann. Rheum. Dis. 71, 524–527 (2012).

    Article  PubMed  Google Scholar 

  147. Brom, M., Moyano, S., Gandino, I. J., Scolnik, M. & Soriano, E. R. Incidence of cancer in a cohort of patients with primary Sjögren syndrome in Argentina. Rheumatol. Int. 39, 1697–1702 (2019).

    Article  CAS  PubMed  Google Scholar 

  148. Kang, J. et al. Risk of malignancy in Korean patients with primary Sjögren’s syndrome. Int. J. Rheum. Dis. 23, 1240–1247 (2020).

    Article  CAS  PubMed  Google Scholar 

  149. Finckh, A. et al. Global epidemiology of rheumatoid arthritis. Nat. Rev. Rheumatol. 18, 591–602 (2022).

    PubMed  Google Scholar 

  150. Barber, M. R. W. et al. Global epidemiology of systemic lupus erythematosus. Nat. Rev. Rheumatol. 17, 515–532 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

  151. Bairkdar, M. et al. Incidence and prevalence of systemic sclerosis globally: a comprehensive systematic review and meta-analysis. Rheumatology 60, 3121–3133 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology, Bicêtre AP-HP Hôpital, Université Paris-Saclay, Paris, France

    Maxime Beydon, Yann Nguyen, Xavier Mariette & Raphaèle Seror

  2. Department of Medicine, University of Wisconsin-Madison, Madison, Wisconsin, USA

    Sara McCoy

  3. Center for Immunology of Viral Infections and Auto-Immune Diseases, INSERM U1184, Université Paris Saclay, Le Kremlin-Bicêtre, France

    Yann Nguyen, Xavier Mariette & Raphaèle Seror

  4. Department of Internal Medicine, University of Tsukuba, Tsukuba, Japan

    Takayuki Sumida

Authors
  1. Maxime Beydon
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sara McCoy
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yann Nguyen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Takayuki Sumida
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Xavier Mariette
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Raphaèle Seror
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

M.B., S.M., Y.N., X.M. and R.S. researched data for the article. All authors made substantial contributions to discussion of the content. M.B., S.M, Y.N., X.M. and R.S. wrote the article. All authors reviewed and/or edited the manuscript before submission.

Corresponding author

Correspondence to Raphaèle Seror.

Ethics declarations

Competing interests

S.M. has received consulting fees from Bristol Myers Squibb, Horizon, iCell, Kiniksa, Novartis, Otsuka, Target RWE and Visterra. X.M. has received consulting fees from Astra Zeneca, Bristol Myers Squibb, Galapagos, GSK, Novartis and Pfizer. R.S. has received consulting fees from Amgen, Bristol Myers Squibb, Boehringer, GSK, Janssen and Pfizer, and travel fees from Amgen and GSK. The remaining authors declare no competing interests.

Peer review

Peer review information

Nature Reviews Rheumatology thanks Debashish Danda, Elizabeth Price and Athanasios Tzioufas for their contribution to the peer review of this work.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Beydon, M., McCoy, S., Nguyen, Y. et al. Epidemiology of Sjögren syndrome. Nat Rev Rheumatol 20, 158–169 (2024). https://doi.org/10.1038/s41584-023-01057-6

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41584-023-01057-6

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing